Marpai enters its May 21 earnings call in a dramatically different position than it held just a month ago — short sellers have largely fled, a fresh Q1 report just hit the tape, and the lending market has all but emptied.
The defining story of the past month is the collapse in short positioning. SI fell 89% over 30 days to just 0.008% of the float — effectively nil for a stock of this size. The peak came around April 15-17, when short shares outstanding were running near 32,000. By May 11 that figure had dropped to roughly 1,800. Whatever thesis drove the April short build has been abandoned at speed, and the borrow market reflects it: availability now reads at 9,999% of short interest, meaning there are vastly more shares available to lend than anyone is currently borrowing. Cost to borrow is 0.54% — a near risk-free rate — down sharply from above 1% in late March and early April. The lending market is as loose as it gets.
The short score confirms the shift. At 25.1 as of May 11 — down from a recent peak above 26.8 at the start of the month — the score has been drifting lower as shorts unwind. The ORTEX factor ranking still places the stock in the 97th percentile for short score rank, which reflects where this name sits in the broader universe historically, not where pressure currently resides. Days-to-cover rank (94th percentile) and utilization rank (95th percentile) tell the same story: the infrastructure for a short attack exists on paper, but actual positioning is negligible right now.
The catalyst for the short exit likely arrived in stages. On May 11, Marpai announced new contract wins across its TPA and MarpaiRx services and flagged a forecast for profitability. The stock responded with a 38% single-day jump. Q1 results, released after the close on May 15, added more texture: EPS came in at -$0.13, a meaningful improvement from -$0.21 in the same quarter last year. Revenue of $4.4M was down year-on-year from $5.4M — the company is still contracting on the top line, but loss reduction is accelerating. The stock dipped 5.3% on May 15, suggesting the market welcomed the improvement but had already priced in some of the optimism from the prior week's bounce.
The ownership structure is heavily insider-dominated. The CEO, Damien Lamendola, holds roughly 26% of shares. The most recent insider data — dated November 2025 and therefore somewhat aged — showed the Founder/Chairman, COO, and two directors all buying at $1.00 per share. With the stock now trading at $0.29, those purchases are deeply underwater. No fresh insider activity is visible in the past 90 days, though stock awards to the CEO and CFO were recorded in October 2025. The prior trajectory bears watching given the May 21 earnings call, where management commentary on the profitability timeline will be the key variable.
Marpai heads into next Wednesday's call with almost no short interest to unwind, a lending market with unlimited room to re-enter bearish positions, and a Q1 print that narrowed losses but didn't reverse the revenue decline. Whether the new contract wins translate into a recovery in the top line — and whether management's profitability forecast carries a timeline — will determine how the stock moves off the catalyst.
See the live data behind this article on ORTEX.
Open MRAI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
